P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME‐LIMITED TREATMENT WITH ANTI‐CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2‐BAG, ‐BCG, ‐BIG AND ‐BIO PHASE‐II TRIALS
Yosifov, Deyan, Tresckow, Julia, Giza, Adam, Robrecht, Sandra, Schneider, Christof, Jebaraj, Billy, Mertens, Daniel, Ritgen, Matthias, Schilhabel, Anke, Kreuzer, Karl‐Anton, Maria Fink, Anna, Al‐Sawaf, Othman, Langerbeins, Petra, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael, Döhner, Hartmut, Stilgenbauer, Stephan, Cramer, Paula, Tausch, Eugen
Published in HemaSphere (08.08.2023)
Published in HemaSphere (08.08.2023)
Get full text
Journal Article
Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax
Fürstenau, Moritz, Weiss, Jonathan, Giza, Adam, Franzen, Fabian, Robrecht, Sandra, Fink, Anna-Maria, Fischer, Kirsten, Schneider, Christof, Tausch, Eugen, Stilgenbauer, Stephan, Ritgen, Matthias, Schilhabel, Anke, Brüggemann, Monika, Eichhorst, Barbara, Hallek, Michael, Cramer, Paula
Published in Clinical cancer research (03.10.2022)
Published in Clinical cancer research (03.10.2022)
Get full text
Journal Article
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut
Huber, Henriette, Tausch, Eugen, Schneider, Christof, Edenhofer, Simone, von Tresckow, Julia, Robrecht, Sandra, Giza, Adam, Zhang, Can, Fürstenau, Moritz, Dreger, Peter, Ritgen, Matthias, Illmer, Thomas, Illert, Anna Lena, Dürig, Jan, Böttcher, Sebastian, Niemann, Carsten U., Kneba, Michael, Al-Sawaf, Othman, Kreuzer, Karl-Anton, Fink, Anna-Maria, Fischer, Kirsten, Döhner, Hartmut, Hallek, Michael, Eichhorst, Barbara, Stilgenbauer, Stephan
Published in Blood (14.09.2023)
Published in Blood (14.09.2023)
Get full text
Journal Article
Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial
Fürstenau, Moritz, Giza, Adam, Weiss, Jonathan, Kleinert, Fanni, Robrecht, Sandra, Franzen, Fabian, Stumpf, Janina, Langerbeins, Petra, Al-Sawaf, Othman, Simon, Florian, Fink, Anna-Maria, Schneider, Christof, Tausch, Eugen, Schetelig, Johannes, Dreger, Peter, Böttcher, Sebastian, Fischer, Kirsten, Kreuzer, Karl-Anton, Ritgen, Matthias, Schilhabel, Anke, Brüggemann, Monika, Stilgenbauer, Stephan, Eichhorst, Barbara, Hallek, Michael, Cramer, Paula
Published in Blood (18.07.2024)
Published in Blood (18.07.2024)
Get full text
Journal Article
Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies
Langerbeins, Petra, Giza, Adam, Robrecht, Sandra, Cramer, Paula, von Tresckow, Julia, Al-Sawaf, Othman, Fink, Anna Maria, Fürstenau, Moritz, Kutsch, Nadine, Simon, Florian, Goede, Valentin, Hoechstetter, Manuela, Niemann, Carsten Utoft, da Cunha-Bang, Caspar, Kater, Arnon, Dubois, Julie, Gregor, Michael, Staber, Philipp Bernhard, Tausch, Eugen, Schneider, Christof, Stilgenbauer, Stephan, Eichhorst, Barbara, Fischer, Kirsten, Hallek, Michael
Published in Blood (20.06.2024)
Published in Blood (20.06.2024)
Get full text
Journal Article
IGLV3-21 R110 Is a Prognostic Marker for Early Stage CLL Patients Under Ibrutinib Treatment or Watch & Wait: Results from the Double-Blind, Randomized, Placebo-Controlled GCLLSG CLL12 Trial
Yosifov, Deyan Y., Robrecht, Sandra, Giza, Adam, Riecke, Armin, Schneider, Christof, Jebaraj, Billy, Jumaa, Hassan, Young, Marc, Müller, Lothar, Vehling-Kaiser, Ursula, Eckart, Michael J., Freier, Werner, Schöttker, Björn, Gaska, Tobias, Reiser, Marcel, Fink, Anna-Maria, Fischer, Kirsten, Eichhorst, Barbara F., Hallek, Michael, Langerbeins, Petra, Stilgenbauer, Stephan, Tausch, Eugen
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
Long-Term Remissions with MRD-Guided Acalabrutinib, Venetoclax and Obinutuzumab in Relapsed/Refractory CLL: Follow-up Efficacy and Circulating Tumor DNA Analysis of the CLL2-Baag Trial
Furstenau, Moritz, Giza, Adam, Fink, Anna-Maria, Robrecht, Sandra, Weiss, Jonathan, Kleinert, Fanni, Schneider, Christof, Tausch, Eugen, Fischer, Kirsten, Langerbeins, Petra, Al-Sawaf, Othman, Schetelig, Johannes, Dreger, Peter, Böttcher, Sebastian, Kreuzer, Karl-Anton, Ritgen, Matthias, Schilhabel, Anke, Brüggemann, Monika, Stilgenbauer, Stephan, Eichhorst, Barbara F., Hallek, Michael, Cramer, Paula
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
Genetic markers and ibrutinib vs placebo treatment in early stage chronic lymphocytic leukemia -results from the GCLLSG CLL12 trial
Riecke, Armin, Tausch, Eugen, Yosifov, Deyan Y., Schneider, Christof, Robrecht, Sandra, Giza, Adam, Müller, Lothar, Vehling-Kaiser, Ursula, Eckart, Michael J., Freier, Werner, Schöttker, Björn, Gaska, Tobias, Reiser, Marcel, Fink, Anna-Maria, Eichhorst, Barbara F., Fischer, Kirsten, Hallek, Michael, Langerbeins, Petra, Stilgenbauer, Stephan
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
MRD-Guided Zanubrutinib, Venetoclax and Obinutuzumab after an Optional Debulking with Bendamustine in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Primary Endpoint Analysis of the Phase 2 CLL2-Bzag Study
Furstenau, Moritz, Giza, Adam, Schneider, Christof, Tausch, Eugen, Robrecht, Sandra, Ritgen, Matthias, Bittenbring, Jörg, Hebart, Holger F., Schöttker, Björn, Illert, Anna Lena, Graeven, Ullrich, Stoltefuss, Andrea, Heinrich, Bernhard, Eckert, Robert, Fink, Anna-Maria, Stumpf, Janina, Simon, Florian, Fischer, Kirsten, Al-Sawaf, Othman, Langerbeins, Petra, Kleinert, Fanni, Weiss, Jonathan, Kreuzer, Karl-Anton, Schilhabel, Anke, Brüggemann, Monika, Eichhorst, Barbara F., Stilgenbauer, Stephan, Hallek, Michael, Cramer, Paula
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/ TP53 mut
Huber, Henriette, Tausch, Eugen, Schneider, Christof, Edenhofer, Simone, von Tresckow, Julia, Robrecht, Sandra, Giza, Adam, Zhang, Can, Fürstenau, Moritz, Dreger, Peter, Ritgen, Matthias, Illmer, Thomas, Illert, Anna Lena, Dürig, Jan, Böttcher, Sebastian, Niemann, Carsten U., Kneba, Michael, Al-Sawaf, Othman, Kreuzer, Karl-Anton, Fink, Anna-Maria, Fischer, Kirsten, Döhner, Hartmut, Hallek, Michael, Eichhorst, Barbara, Stilgenbauer, Stephan
Published in Blood (14.09.2023)
Published in Blood (14.09.2023)
Get full text
Journal Article
Treatment with idelalisib in patients with chronic lymphocytic leukemia – real world data from the registry of the German CLL Study Group
von Tresckow, Julia, Heyl, Nikola, Robrecht, Sandra, Giza, Adam, Aldaoud, Ali, Schlag, Rudolf, Klausmann, Martine, Linde, Hartmut, Stein, Wolfgang, Schwarzer, Andreas, Fischer, Kirsten, Cramer, Paula, Eichhorst, Barbara, Hallek, Michael, Fink, Anna Maria
Published in Annals of hematology (01.11.2023)
Published in Annals of hematology (01.11.2023)
Get full text
Journal Article
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations
Cramer, Paula, Tausch, Eugen, von Tresckow, Julia, Giza, Adam, Robrecht, Sandra, Schneider, Christof, Fürstenau, Moritz, Langerbeins, Petra, Al-Sawaf, Othman, Pelzer, Benedikt W., Fink, Anna Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Eichhorst, Barbara, Kneba, Michael, Stilgenbauer, Stephan, Hallek, Michael
Published in Blood (11.11.2021)
Published in Blood (11.11.2021)
Get full text
Journal Article
Pooled Analysis of First-Line Treatment with Targeted Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Aged 80 Years and Older
Simon, Florian, Giza, Adam, Robrecht, Sandra, Fink, Anna-Maria, Cramer, Paula, Von Tresckow, Julia, Fürstenau, Moritz, Goede, Valentin, Tausch, Eugen, Schneider, Christof, Stilgenbauer, Stephan, Wendtner, Clemens-Martin, Eichhorst, Barbara, Fischer, Kirsten, Hallek, Michael, Al-Sawaf, Othman
Published in Blood (23.11.2021)
Published in Blood (23.11.2021)
Get full text
Journal Article
The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia
Al-Sawaf, Othman, Fürstenau, Moritz, Giza, Adam, Robrecht, Sandra, Von Tresckow, Julia, Fink, Anna Maria, Simon, Florian, Tausch, Eugen, Schneider, Christof, Sivcheva, Liliya, Schwarer, Anthony, Loscertales, Javier, Weinkove, Robert, Strumberg, Dirk, Kilfoyle, Allanah R., Juliusson, Gunnar, Da Cunha-Bang, Caspar, Illmer, Thomas, Gregor, Michael, Thornton, Patrick, Janssens, Ann, Tadmor, Tamar, Lindström, Vesa, Staber, Philipp Bernhard, Levin, Mark-David, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Ritgen, Matthias, Stilgenbauer, Stephan, Kater, Arnon P., Niemann, Carsten Utoft, Fischer, Kirsten, Eichhorst, Barbara F., Hallek, Michael
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry
Kutsch, Nadine, Fink, Anna Maria, Federhen, Anno, Giza, Adam, Robrecht, Sandra, Stumpf, Janina, Stoltefuß, Andrea, Vehling-Kaiser, Ursula, Koenigsmann, Michael, Tausch, Eugen, Schneider, Christof, Stilgenbauer, Stephan, Illmer, Thomas, Schlag, Rudolf, Dörfel, Steffen, Gaska, Tobias, Kiehl, Michael G., Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation
Huber, Henriette, Tausch, Eugen, Schneider, Christof, Edenhofer, Simone, Von Tresckow, Julia, Robrecht, Sandra, Giza, Adam, Zhang, Can, Furstenau, Moritz, Dreger, Peter, Ritgen, Matthias, Illmer, Thomas, Illert, Anna Lena, Dürig, Jan, Böttcher, Sebastian, Niemann, Carsten Utoft, Kneba, Michael, Fink, Anna-Maria, Fischer, Kirsten, Döhner, Hartmut, Hallek, Michael, Eichhorst, Barbara, Stilgenbauer, Stephan
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations
Langerbeins, Petra, Giza, Adam, Robrecht, Sandra, Cramer, Paula, Tresckow, Julia, Al‐Sawaf, Othman, Fink, Anna Maria, Fürstenau, Moritz, Kater, Arnon P., Spek, Ellen, Niemann, Carsten Utoft, Cunha‐Bang, Caspar, Tausch, Eugen, Schneider, Christof, Stilgenbauer, Stephan, Fischer, Kirsten, Hallek, Michael, Eichhorst, Barbara
Published in American journal of hematology (01.08.2024)
Published in American journal of hematology (01.08.2024)
Get full text
Journal Article
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2‐BCG): Final analysis of a multicenter, open‐label phase‐II‐trial
Cramer, Paula, Tresckow, Julia, Fink, Anna‐Maria, Robrecht, Sandra, Giza, Adam, Tausch, Eugen, Müller, Lothar, Knauf, Wolfgang, Zingerle, Matthias, Al‐Sawaf, Othman, Langerbeins, Petra, Fischer, Kirsten, Kreuzer, Karl‐Anton, Kneba, Michael, Wendtner, Clemens‐Martin, Stilgenbauer, Stephan, Eichhorst, Barbara, Hallek, Michael
Published in American journal of hematology (01.06.2024)
Published in American journal of hematology (01.06.2024)
Get full text
Journal Article
Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia
Bloehdorn, Johannes, Braun, Andrejs, Taylor-Weiner, Amaro, Jebaraj, Billy Michael Chelliah, Robrecht, Sandra, Krzykalla, Julia, Pan, Heng, Giza, Adam, Akylzhanova, Gulnara, Holzmann, Karlheinz, Scheffold, Annika, Johnston, Harvey E, Yeh, Ru-Fang, Klymenko, Tetyana, Tausch, Eugen, Eichhorst, Barbara, Bullinger, Lars, Fischer, Kirsten, Weisser, Martin, Robak, Tadeusz, Schneider, Christof, Gribben, John, Dahal, Lekh N, Carter, Mathew J, Elemento, Olivier, Landau, Dan A, Neuberg, Donna S, Cragg, Mark S, Benner, Axel, Hallek, Michael, Wu, Catherine J, Döhner, Hartmut, Stilgenbauer, Stephan, Mertens, Daniel
Published in Nature communications (13.09.2021)
Published in Nature communications (13.09.2021)
Get full text
Journal Article